Pharos Capital Group acquired Lafayette, Ind.-based Horizon Oncology and concurrently launched its own venture, Verdi Oncology.
Here's what you should know.
1. Verdi is an oncology practice and clinical research management company. Wes Chapman, a Pharos Capital partner, will serve as the firm's CEO.
2. The terms of the transaction were not disclosed.
3. Horizon has four oncology and hematology providers. The practice offers clinical trial opportunities to its patients.
4. Horizon Founder Wael Harb, MD, said he was "excited to partner with Pharos and Verdi."